✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

Best Cosmetic Peptides: GHK-Cu, AHK-Cu, Melanotan II and the Collagen/Hair/Pigmentation Research Compounds

“Cosmetic peptide” in the research-literature sense covers three distinct endpoint families — collagen and extracellular matrix research (anti-aging, wound healing, scar remodelling), hair-follicle / stem-cell activation research (alopecia, follicle regeneration), and pigmentation research (melanocortin pharmacology, melanin synthesis). The seven peptides on the MedsBase catalogue with substantive cosmetic-research applicability are ranked below, with mechanism class, product link, and the specific research scenario each fits best.

How to use this hub

Each pick below carries: mechanism class, receptor or biological target, manufacturer / source flag, link to the product page, link to the dedicated research guide (where one is published), and a “pick for” research scenario summary.

• Collagen / matrix / wound-healing research: GHK-Cu, GLOW Blend, BPC-157 (tissue-repair crossover).
• Hair-follicle / stem-cell research: AHK-Cu, GHK-Cu (both have published follicle-activation data).
• Pigmentation / melanocortin research: Melanotan II.
• Sexual / cosmetic-crossover: PT-141 (bremelanotide).

1. GHK-Cu (copper tripeptide; the prototype cosmetic peptide)

Mechanism class: Copper-chelated tripeptide (Gly-His-Lys-Cu) · CAS: 89030-95-5 · View product · Anti-aging mechanism guide · Hair-loss research guide

GHK-Cu is the most-researched cosmetic peptide and the prototype copper-chelate research compound. The native tripeptide (Gly-His-Lys) is naturally present in human plasma at concentrations that decline with age — and the Cu(II)-chelated form has documented effects on multiple cosmetic-research endpoints: collagen synthesis upregulation (via TGF-β1 pathway activation), extracellular matrix remodelling (decorin and proteoglycan synthesis), hair-follicle stem-cell activation (with published photographic-endpoint research), and wound healing acceleration (the original 1970s research finding that established the molecule). The activity profile depends specifically on the copper-chelate form; the free peptide is largely inactive at these endpoints.

Research applications span topical formulation work, injectable mesotherapy protocols, and ex-vivo skin / hair-follicle culture systems. The molecule is the cosmetic-peptide equivalent of BPC-157 in the recovery cluster — the single most-published compound, with the deepest body of mechanism research.

Pick for: any collagen / matrix / wound-healing research scenario; the reference compound for cosmetic-peptide research; primary or secondary endpoint in anti-aging protocol design.

2. AHK-Cu (hair-specific copper tripeptide analogue)

Mechanism class: Copper-chelated tripeptide (Ala-His-Lys-Cu); hair-follicle-selective · View product

AHK-Cu replaces the N-terminal glycine of GHK with alanine — a single-residue substitution that preserves copper-chelate binding while shifting the activity profile toward hair-follicle-selective effects. Published research shows AHK-Cu activates dermal-papilla cells (the follicle’s signalling hub) more efficiently than GHK-Cu at matched concentrations, with measurable hair-shaft thickening and anagen-phase prolongation in in vitro follicle-culture models. The research framing is narrower than GHK-Cu’s broad anti-aging applicability — AHK-Cu is studied predominantly in the alopecia / regenerative-hair-research literature rather than the general skin-aging literature.

Pick for: hair-specific research where follicle-selective activity is the endpoint; protocols that want a non-finasteride, non-minoxidil mechanism arm.

3. GLOW Blend (BPC-157 + GHK-Cu + TB-500 tri-compound research bundle)

Mechanism class: Three-compound combination — tissue repair + collagen / matrix · View product

GLOW Blend is the research-bundle option for protocols that bridge the cosmetic-collagen research cluster with the tissue-repair research cluster. The combination — BPC-157 (gastrointestinal and tissue protection compound), GHK-Cu (cosmetic-collagen mechanism), TB-500 (thymosin β-4 actin-binding tissue repair) — covers both endpoint families in a single vial. Common research scenarios include skin-wound healing studies where both matrix remodelling and tissue-repair endpoints are measured, dermatologic regeneration protocols, and combined cosmetic + therapeutic dermatology models.

Pick for: protocols spanning cosmetic and tissue-repair endpoints; budget-conscious research bundles where three-vial sourcing is impractical.

4. Melanotan II (synthetic α-MSH analogue; pigmentation research)

Mechanism class: Cyclic heptapeptide melanocortin agonist (MC1R / MC3R / MC4R / MC5R nonselective) · View product · Full research guide

Melanotan II is the synthetic analogue of native α-melanocyte-stimulating hormone (α-MSH) used in pigmentation research. The molecule activates all four melanocortin receptors with overlapping but distinct affinity profiles — MC1R activation drives melanin synthesis in melanocytes (the pigmentation endpoint), MC4R activation drives the sexual-response effects (which is what made bremelanotide / PT-141 the FDA-approved offshoot), and MC3R/MC5R activation explains some of the secondary effects observed in published studies. The non-selective receptor profile is also the source of the molecule’s well-documented side-effect signature in published research: nausea, flushing, transient appetite suppression, and changes in pigmentation distribution.

Pick for: melanocortin pharmacology research; pigmentation / melanin-synthesis endpoint studies; the parent compound for PT-141 / bremelanotide mechanism research.

5. BPC-157 (tissue repair with cosmetic / dermal-research crossover)

Mechanism class: 15-amino-acid synthetic body-protection compound fragment · View product · Full research guide

BPC-157 lives primarily in the tissue-repair cluster but has published cosmetic / dermatologic crossover research worth surfacing here. Mechanism studies show effects on dermal wound healing, angiogenesis in skin-repair models, and synergy with GHK-Cu in matrix-remodelling endpoints. In cosmetic-research protocol design, BPC-157 is most-used as the systemic / tissue-repair arm paired with topical or local GHK-Cu — combining the two molecules covers both the local matrix endpoint (GHK-Cu) and the systemic repair endpoint (BPC-157).

Pick for: dermal wound-healing research; tissue-repair-with-cosmetic-readout protocols; the systemic arm of GHK-Cu-centred research designs.

6. TB-500 (thymosin β-4; tissue repair with dermal-research applications)

Mechanism class: Synthetic thymosin β-4 fragment; actin-binding tissue repair · View product · Full research guide

TB-500’s primary research applications are in the tissue-repair cluster, but the molecule has substantive dermal applicability through its effects on cell migration, angiogenesis, and actin polymerization in wound-healing models. In cosmetic-research design, TB-500 is the most-paired complement to GHK-Cu in scar-remodelling and post-procedural recovery protocols. The pairing is built into the GLOW Blend (above).

Pick for: scar-remodelling research; angiogenic / wound-vascularization endpoints; the systemic-repair arm of cosmetic-research designs.

7. PT-141 / Bremelanotide (cosmetic-pharmacology crossover from the melanocortin family)

Mechanism class: Selective MC3R / MC4R melanocortin agonist · Comparator drug: Vyleesi (FDA-approved 2019 for hypoactive sexual desire disorder) · View product · Full research guide

PT-141 (bremelanotide) is the receptor-selective analogue of Melanotan II — the cyclic-heptapeptide architecture is retained, but residue substitutions shift receptor affinity toward MC3R / MC4R selectivity and away from MC1R. The selectivity shift removed most of the pigmentation activity (which is MC1R-mediated) and preserved the sexual-response activity (which is MC4R-mediated), which is why bremelanotide became the FDA-approved offshoot rather than Melanotan II itself. PT-141 sits in the cosmetic-peptide hub primarily as the comparator molecule for melanocortin-receptor-selectivity research — protocols studying how single-residue substitutions in the MSH backbone reshape downstream receptor selectivity use PT-141 as the canonical example.

Pick for: melanocortin-receptor-selectivity research; protocols using PT-141 as the receptor-selective comparator to Melanotan II’s non-selective activity.

Comparison table

The GHK-Cu copper-chelate dependence — why the form matters

One detail worth surfacing because researchers new to the cosmetic-peptide cluster often miss it: GHK-Cu and AHK-Cu both require the Cu(II)-chelated form to produce their published research effects. The free tripeptide (without copper) has measurable but substantially smaller activity at the relevant endpoints — typical published comparisons show the Cu-chelate form produces 5-10x larger collagen-synthesis effects than the free peptide at matched concentrations. The research-grade material on the MedsBase catalogue ships as the Cu-chelated form; the CAS number 89030-95-5 (GHK-Cu) refers specifically to this chelated complex, not the free peptide. Protocols using “GHK” as a free-peptide reference compound need to source the free form separately and recognise that the published effect-size literature predominantly references the chelated form.

Frequently asked research questions

Why is GHK-Cu always paired with copper but other peptides on this list aren’t?

The activity of GHK-Cu and AHK-Cu at their published cosmetic endpoints — collagen synthesis, extracellular matrix remodelling, hair-follicle stem-cell activation — depends specifically on the Cu(II)-chelated form of the tripeptide, not the free peptide. The molecule’s published effect sizes reference the chelated form, and the standard CAS registration (89030-95-5 for GHK-Cu) is for the chelated complex. The other peptides on this page (BPC-157, TB-500, Melanotan II, PT-141) work through receptor-pharmacology mechanisms that do not require metal chelation; their free-peptide or acetate-salt forms are the active research-grade compounds.

What’s the practical difference between GHK-Cu and AHK-Cu?

A single-residue substitution — alanine replacing glycine at the N-terminus. The substitution preserves copper-chelate binding but shifts the activity profile toward hair-follicle-selective effects. Published research shows AHK-Cu activates dermal-papilla cells (the follicle’s signalling hub) more efficiently than GHK-Cu at matched concentrations. GHK-Cu has broader applicability across the cosmetic-research literature (collagen, matrix, wound healing, hair follicle); AHK-Cu is narrower but more potent specifically at the follicle endpoint.

How is Melanotan II different from PT-141 / bremelanotide?

Both are cyclic-heptapeptide melanocortin analogues with similar backbones, but residue substitutions in PT-141 shift receptor affinity toward MC3R/MC4R selectivity and away from MC1R. The selectivity shift removed most of the pigmentation activity (which is MC1R-mediated) and preserved the sexual-response activity (MC4R-mediated). For pigmentation research, Melanotan II is the active compound; for the sexual-response endpoint or for receptor-selectivity comparator research, PT-141 is the receptor-selective analogue. PT-141’s comparator drug Vyleesi is FDA-approved for HSDD; Melanotan II has no approved indication.

Can GHK-Cu work topically or does it require injection?

Published research uses both routes. Topical formulations (creams, serums, mesotherapy gels) deliver the chelated peptide through stratum-corneum-permeable vehicles; subcutaneous injection delivers it systemically at higher bioavailability. The published effect-size literature includes both topical and SC routes, with topical formulations dominating in the cosmetic-research literature and SC dominating in wound-healing research. Both routes are valid research design choices; selection depends on the endpoint and the research model.

What is the GLOW Blend’s composition?

BPC-157 10 mg + GHK-Cu 50 mg + TB-500 10 mg per vial. The blend bridges the cosmetic-collagen research cluster (GHK-Cu) with the tissue-repair research cluster (BPC-157 + TB-500). Useful for research protocols that measure both endpoint families in the same experimental design — for example, dermal-wound healing studies where matrix remodelling and tissue repair are both primary endpoints.

Is there a hair-loss-specific protocol for combining GHK-Cu with AHK-Cu?

The published research includes protocols combining the two — typically with GHK-Cu as the broader-mechanism baseline (covering matrix remodelling, anti-inflammatory effects, and a portion of the follicle activity) and AHK-Cu as the follicle-selective amplifier. The mechanistic logic: GHK-Cu addresses multiple skin / scalp-tissue pathways at once, while AHK-Cu is more concentrated activity at the dermal papilla specifically. The MedsBase GHK-Cu hair-loss research guide covers the protocol design in detail.

How does cosmetic-peptide research relate to finasteride / minoxidil research in hair loss?

Different mechanism families. Finasteride works through 5α-reductase inhibition (suppressing DHT). Minoxidil works through vasodilatory / potassium-channel-opener effects on follicle blood supply. The copper peptides (AHK-Cu / GHK-Cu) work through direct dermal-papilla activation and matrix-environment effects on the follicle stem-cell niche. The three pathways are non-overlapping, which is why combined research protocols use peptides as an additional mechanism arm alongside the established small-molecule treatments rather than as direct comparators.

What’s the storage protocol for copper peptides?

Same as the rest of the catalogue: lyophilized vials at -20 °C long-term or 2-8 °C as working stock; reconstituted solution at 2-8 °C with use within ~30 days; protect from light; never freeze-thaw the reconstituted solution. The copper-chelate form is stable under these conditions; copper-mediated oxidation of adjacent residues is not a documented concern at the working concentrations and timeframes used in cosmetic-peptide research.

Bottom line

The cosmetic-peptide cluster reduces to three primary research scenarios. For collagen / matrix / wound-healing research, GHK-Cu is the reference compound — the most-published cosmetic peptide and the prototype copper-chelate research molecule. For hair-loss research, AHK-Cu provides the follicle-selective amplifier, often paired with GHK-Cu’s broader mechanism. For pigmentation research, Melanotan II is the non-selective melanocortin agonist; PT-141 sits alongside it as the receptor-selective comparator. The GLOW Blend pre-bundles the cosmetic-collagen and tissue-repair sides for protocols that need both endpoints in a single vial. BPC-157 and TB-500 are tissue-repair primary compounds with cosmetic crossover; they’re surfaced here because cosmetic-research protocol design often pairs them with GHK-Cu.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.